Avacta Group (LON:AVCT) Stock Price Up 14.7% - Still a Buy?

Key Points

• Avacta Group's stock price rose by 14.7%, reaching GBX 54.50 ($0.73), with trading volume increasing by 181% compared to its average daily volume.
• The biotechnology firm reported a negative earnings per share of GBX (8.54) (($0.11)) for the quarter, with analysts predicting a further decline to -9.90 for the current year.
• Despite recent stock performance, the company has a significant negative net margin of 114.45% and a high debt-to-equity ratio of 52.53, raising concerns about its financial stability.

Avacta Group Plc (LON:AVCT - Get Free Report) shares traded up 14.7% on Wednesday . The stock traded as high as GBX 54.85 ($0.73) and last traded at GBX 54.50 ($0.72). 5,689,326 shares were traded during trading, an increase of 181% from the average session volume of 2,025,171 shares. The stock had previously closed at GBX 47.50 ($0.63).

Avacta Group Trading Down 7.4%

The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53. The stock has a market cap of £181.21 million, a P/E ratio of -6.14 and a beta of 1.12. The firm's 50-day simple moving average is GBX 34.67 and its 200 day simple moving average is GBX 37.78.

Avacta Group (LON:AVCT - Get Free Report) last posted its quarterly earnings data on Friday, June 6th. The biotechnology company reported GBX (8.54) (($0.11)) earnings per share (EPS) for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. As a group, equities research analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).